<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618283/" ref="ordinalpos=3666&amp;ncbi_uid=4785377&amp;link_uid=PMC3618283" image-link="/pmc/articles/PMC3618283/figure/F1/" class="imagepopup">Figure 1.  From: Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>. </a></div><br /><div class="p4l_captionBody">A simplified version of the insulin signaling pathway. Insulin or insulin-like growth factor (IGF) binds to the insulin/IGF receptor causing autophosphorylation and activation. This leads to activation of phosphoinositide-3-kinase (PI3kinase), and the end result is to phosphorylate and activate Akt and phosphorylate and deactivate glycogen synthase kinase-3 (GSK-3). Active GSK-3 deactivates glycogen synthase and eukaryotic initiation factor 2B (eIF2B) and activates insulin receptor substrate-1 (IRS-1; an inhibitor of the insulin receptor). PIP3, phosphoinositide 3,4,5-tris-phosphate; PKC, protein kinase C (adapted and modified with permission from Gould and Manji49).</div></div>